500 patients67,039 observations150 daysLIVE

Patient P-03193

Synthetic patientONX-7 · Day 115 · 55–64 · M · baseline S13Open companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
21%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S13
  2. Day 14 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 18 DT-01 recommendedDosing / Timing Recommendation DT-01
  4. Day 19 Patient acceptedStarted DT-01 in the companion
  5. Day 24 GI symptom burden −17% vs expectedDosing / Timing Recommendation DT-01
  6. Day 30 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 14.

Primary contributors, last 14 days
  • GI instability+8
  • Nutritional resilience+2

What helped?

  • Dosing / Timing Recommendation DT-01Day 18
    Result: symptom burden −17%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients.

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Autonomic recovery 45
    • WearableResting HR 74 bpm
    • Wearable3,668 steps/day
  • Butyrate / short-chain fatty acid production 35
    • MicrobiomeButyrate capacity 44/100
  • Drug metabolism and exposure 35
    • DNADPYD *2A → slower clearance
  • Inflammatory signalling 20
    • MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 44/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
68 ms
Sleep
7.0 h
Steps
3,251
Resting HR
72 bpm
Daily log: GI score 18, nutritional resilience 64, adherence 100.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0340856%S09HY-01improved53
P-0306751%S06DT-01no change50
P-0344250%S11DT-01improved51
P-0333949%S1949
P-0306248%S1144
P-0316748%S1853
P-0320347%S1056
P-0309746%S1660
P-0311446%S11DT-01improved48
P-0337546%S09DT-01improved52
P-0304045%S0351
P-0314345%S11DT-01improved49